MDxHealth SA (NASDAQ:MDXH) Short Interest Down 42.8% in May

MDxHealth SA (NASDAQ:MDXH - Get Free Report) was the target of a large drop in short interest during the month of May. As of May 31st, there was short interest totalling 41,100 shares, a drop of 42.8% from the May 15th total of 71,900 shares. Approximately 0.1% of the company's shares are short sold. Based on an average trading volume of 67,700 shares, the short-interest ratio is currently 0.6 days.

Analyst Ratings Changes

Separately, Wall Street Zen raised MDxHealth to a "hold" rating in a research note on Saturday, May 24th.

Institutional Investors Weigh In On MDxHealth

Institutional investors have recently modified their holdings of the stock. AWM Investment Company Inc. raised its holdings in MDxHealth by 10.6% in the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock worth $7,414,000 after purchasing an additional 499,992 shares during the period. Delta Investment Management LLC raised its stake in shares of MDxHealth by 459.1% in the first quarter. Delta Investment Management LLC now owns 190,100 shares of the company's stock worth $270,000 after buying an additional 156,100 shares during the period. Perkins Capital Management Inc. lifted its position in shares of MDxHealth by 20.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock valued at $1,678,000 after buying an additional 198,000 shares in the last quarter. Castleview Partners LLC bought a new position in shares of MDxHealth during the 1st quarter valued at approximately $48,000. Finally, FAS Wealth Partners Inc. increased its holdings in MDxHealth by 49.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock worth $58,000 after acquiring an additional 8,100 shares in the last quarter.

MDxHealth Trading Down 0.5%

MDXH stock traded down $0.01 on Monday, reaching $1.99. The company's stock had a trading volume of 59,498 shares, compared to its average volume of 88,232. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54. The business has a fifty day simple moving average of $1.85 and a two-hundred day simple moving average of $1.88. The firm has a market cap of $94.10 million, a PE ratio of -1.31 and a beta of 1.30. MDxHealth has a 12-month low of $1.35 and a 12-month high of $3.50.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.06). MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The company had revenue of $24.29 million for the quarter, compared to the consensus estimate of $22.62 million. As a group, research analysts forecast that MDxHealth will post -1.15 EPS for the current year.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.